Xbrane Biopharma AB

Research Xbrane Biopharma AB (XBRANE) on Bullrun: market cap SEK 214.30M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerXBRANE
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencySEK
• Market capSEK 214.30M
• Financial periodQ4 2025
• RevenueSEK 9.10M
• Net income-SEK 26.48M
• Free cash flow-SEK 67.56M
• Gross margin18.5%

Valuation Snapshot

latest market cap is SEK 214.30M.

About Xbrane Biopharma AB

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults.

Frequently asked questions

What is Xbrane Biopharma AB's market cap?

Xbrane Biopharma AB's market capitalization is SEK 214.30M.

What does Xbrane Biopharma AB do?

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic...